These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8111643)

  • 1. [Organic germanium: its toxic effect and function in medical care].
    Kong X
    Zhonghua Yi Xue Za Zhi; 1993 Aug; 73(8):454-6. PubMed ID: 8111643
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II Eastern Cooperative Oncology Group Study of spirogermanium in previously treated lymphoma.
    Boros L; Tsiatis AA; Neiman RS; Mann RB; Glick JH
    Cancer Treat Rep; 1986 Jul; 70(7):917-8. PubMed ID: 3719586
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II study of spirogermanium in the treatment of metastatic breast cancer.
    Pinnamaneni K; Yap HY; Legha SS; Blumenschein GR; Bodey GP
    Cancer Treat Rep; 1984 Sep; 68(9):1197-8. PubMed ID: 6478457
    [No Abstract]   [Full Text] [Related]  

  • 4. Continuous-infusion spirogermanium for the treatment of refractory carcinoma of the ovary: a phase II trial.
    Kavanagh JJ; Saul PB; Copeland LJ; Gershenson DM; Krakoff IH
    Cancer Treat Rep; 1985 Jan; 69(1):139-40. PubMed ID: 3967257
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II trial of spirogermanium in breast adenocarcinoma: a Cancer and Leukemia Group B Study.
    Budman DR; Ginsberg S; Perry M; Weinberg V; Schein P; Hanson J; Coleman M; Wood W
    Cancer Treat Rep; 1982 Aug; 66(8):1667-8. PubMed ID: 7105058
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II trial of spirogermanium in advanced epithelial carcinoma of the ovary.
    Weiselberg L; Budman DR; Schulman P; Vinciguerra V; Degnan TJ; Pasmantier M
    Cancer Treat Rep; 1982 Aug; 66(8):1675-6. PubMed ID: 7201885
    [No Abstract]   [Full Text] [Related]  

  • 7. [Toxicity of an organic Germanium compound: deleterious consequences of a "natural remedy"].
    Raisin J; Hess B; Blatter M; Zimmermann A; Descoeudres C; Horber FF; Jaeger P
    Schweiz Med Wochenschr; 1992 Jan; 122(1-2):11-3. PubMed ID: 1594900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of spirogermanium for treatment of advanced breast cancer.
    Falkson G; Falkson HC
    Cancer Treat Rep; 1983 Feb; 67(2):189-90. PubMed ID: 6825129
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study.
    Ettinger DS; Finkelstein DM; Donehower RC; Chang AY; Green M; Blum R; Hahn RG; Ruckdeschel JC
    Med Pediatr Oncol; 1989; 17(3):197-201. PubMed ID: 2546026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965)].
    Bui NB; Chauvergne J; Brunet R; Richaud P; Hoerni B; Lagarde C; Le Guillou M
    Bull Cancer; 1986; 73(1):65-7. PubMed ID: 3779124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of carboxyethylgermanium sesquioxide on the methylcholanthrene-induced tumorigenesis in mice.
    Kumano N; Nakai Y; Ishikawa T; Koinumaru S; Suzuki S; Konno K
    Sci Rep Res Inst Tohoku Univ Med; 1978 Dec; 25(3-4):89-95. PubMed ID: 752926
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study.
    Eisenhauer E; Quirt I; Connors JM; Maroun J; Skillings J
    Invest New Drugs; 1985; 3(3):307-10. PubMed ID: 4066225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of spirogermanium in patients with metastatic malignant melanoma. An NCI Canada Clinical Trials Group Study.
    Eisenhauer E; Kerr I; Bodurtha A; Iscoe N; McCulloch P; Pritchard K; Quirt I
    Invest New Drugs; 1985; 3(3):303-5. PubMed ID: 4066224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor properties of organometallic metallocene complexes of tin and germanium.
    Köpf-Maier P; Janiak C; Schumann H
    J Cancer Res Clin Oncol; 1988; 114(5):502-6. PubMed ID: 3182909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hazard assessment of germanium supplements.
    Tao SH; Bolger PM
    Regul Toxicol Pharmacol; 1997 Jun; 25(3):211-9. PubMed ID: 9237323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of health promotive effect of organometallic germanium compounds].
    Wang YL
    Zhonghua Yu Fang Yi Xue Za Zhi; 1994 Nov; 28(6):372-4. PubMed ID: 7867458
    [No Abstract]   [Full Text] [Related]  

  • 17. Pulmonary toxicity associated with spirogermanium.
    Dixon C; Hagemeister F; Legha S; Bodey G
    Cancer Treat Rep; 1984 Jun; 68(6):907-8. PubMed ID: 6733705
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic effects of organic germanium.
    Goodman S
    Med Hypotheses; 1988 Jul; 26(3):207-15. PubMed ID: 3043151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experimental study on prevention of the colorectal cancer by China medical stone and the organgermanium compound].
    Song WS
    Zhonghua Yu Fang Yi Xue Za Zhi; 1993 Sep; 27(5):286-9. PubMed ID: 8137660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of spirogermanium in patients with advanced carcinoma of the cervix.
    Brenner DE; Rosenshein NB; Dillon M; Jones HW; Forastiere A; Tipping S; Burnett LS; Greco FA; Wiernik PH
    Cancer Treat Rep; 1985 Apr; 69(4):457-8. PubMed ID: 3995514
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.